Products for Research Use Only

GZ-793A

CAT: 0804-HY-117883-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-117883-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
GZ-793A is an orally active and selective vesicular monoamine transporter-2 (VMAT2) inhibitor, with an Ki of 0.029 μM. GZ-793A inhibits the neurochemical effects of methamphetamine (METH) -induced dopamine release. GZ-793A can be used for research of METH addiction[1][2][3].
CAS Number
1356447-90-9
UNSPSC
12352005
Hazard Statement
H410
Target
Monoamine Transporter
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/gz-793a.html
Purity
99.50
Solubility
H2O : 3 mg/mL (ultrasonic; warming)
Smiles
OC[C@H](O)CN1[C@H](CCC[C@H]1CCC2=CC=C(C=C2)OC)CCC3=CC=C(C=C3)OC.Cl
Molecular Formula
C26H38ClNO4
Molecular Weight
464.04
Precautions
H410
References & Citations
[1]Wilmouth CE, et al. Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats. Pharmacol Biochem Behav. 2013 Nov;112:29-33.|[2]Nickell JR, et al. GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2. Eur J Pharmacol. 2017 Jan 15;795:143-149.|[3]Nickell JR, et al. The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse. Adv Pharmacol. 2014;69:71-106.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported